Segmented linear correlations between bone scan index and prostate cancer biomarkers, alkaline phosphatase, and prostate specific antigen in patients with a Gleason score ≥7.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
24 Jun 2022
24 Jun 2022
Historique:
received:
18
10
2021
accepted:
06
05
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
Technetium-99m methyl diphosphonate bone scintigraphy is relatively easily accessible for detecting bone metastases in prostate cancer patients. However, it is subjective and can be challenging to compare images taken at different time points. The bone scan index (BSI) is a more objective evaluation and allows for better comparison of images. Its correlation with other biomarkers of prostate cancer metastases such as prostate specific antigen (PSA) and alkaline phosphatase (ALP) is not clearly understood. This study thus aimed to compare the BSI correlation to PSA against that of BSI to ALP levels in patients with a Gleason score ≥7.A retrospective analysis of the medical records of 50 prostate cancer patients with a Gleason score of ≥7 referred for a bone scan between January 1, 2015 and December 31, 2018 was undertaken. Bone scans were interpreted visually, and using a semi-automated computer programme to quantify the BSI and its relation to PSA and ALP measurements.For the metastasis positive measurements, there was a statistically significant moderate positive overall linear correlation between BSI and PSA. For ALP and BSI, there were 2 segmented strong positive linear relationships between them. The first segment consisted of ALP < 375 IU/L and BSI >10%, where ALP and BSI were strongly and positively correlated. The other segment tended to have generally low BSI measurements (<10%) and also had a strong and positive correlation.The BSI was found to be better linearly correlated with ALP than PSA.
Identifiants
pubmed: 35758394
doi: 10.1097/MD.0000000000029515
pii: 00005792-202206240-00051
pmc: PMC9276229
doi:
Substances chimiques
Biomarkers, Tumor
0
Alkaline Phosphatase
EC 3.1.3.1
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29515Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Chien T-M, Lu Y-M, Geng J-H, et al. Predictors of positive bone metastasis in newly diagnosed prostate cancer patients. Asian Pac J Cancer Prev 2016;17:1187–91.
Zhou J, Gou Z, Wu R, et al. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol 2019;48:1915–24.
Shen G, Deng H, Hu S, et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 2014;43:1503–13.
Johnston AW, Longo TA, Davis LG, et al. Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study. Int Braz J Urol 2020;46:42–52.
Nakajima K, Edenbrandt L, Mizokami A. Bone scan index: a new biomarker of bone metastasis in patients with prostate cancer. Int J Urol 2017;24:668–73.
Imbriaco M, Larson SM, Yeung HW, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 1998;4:1765–72.
Wymenga LFA, Boomsma JHB, Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 2001;88:226–30.
Chaoying L, Chao M, Xiangrui Y, et al. Risk factors of bone metastasis in patients with newly diagnosed prostate cancer. Eur Rev Med Pharmacol Sci 2022;26:391–8.
Akimoto S, Furuya Y, Akakura K, et al. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase. Int J Urol 1997;4:572–5.
Yordanova A, Linden P, Hauser S, et al. The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu] Lu-PSMA therapy. Prostate 2020;80:17–27.
Li D, Ly H, Hao X, et al. Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis. Cancer Manage Res 2018;10:3125–39.
Heinrich D, Bruland Ø, Guise TA, et al. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Fut Oncol 2018;14:2543–56.
Mota JM, Armstrong AJ, Larson SM, et al. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. Prostate Cancer Prostatic Dis 2019;22:522–30.
Kaboteh R, Damber J-E, Gjertsson P, et al. Bone scan index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res 2013;3:09–14.
Shah RB, Zhou M. Recent advances in prostate cancer pathology: Gleason grading and beyond. Pathol Int 2016;66:260–72.
Fizazi K, Flaig TW, Stöckle M, et al. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol 2016;27:699–705.
Donohoe KJ, Cohen EJ, Giammarile F, et al. Appropriate use criteria for bone scintigraphy in prostate and breast cancer. J Nucl Med 2017;58:14N–7N.
Janane A, Jawad C, Hajji F, et al. Bone scan findings in a North African ethnic group and relation to PSA levels and gleason score of the biopsy. Actas Urol Esp 2011;35:534–9.
McArthur C, McLaughlin G, Meddings RN. Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients. Br J Radiol 2012;85:390–4.
Caglar M, Tuncel M, Yildiz E, et al. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT. Ann Nucl Med 2020;34:932–41.
Mitsui Y, Shiina H, Yamamoto Y, et al. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int 2012;110:E628–34.
Anand A, Morris MJ, Kaboteh R, et al. A preanalytic validation study of automated bone scan index: effect on accuracy and reproducibility due to the procedural variabilities in bone scan image acquisition. J Nucl Med 2016;57:1865–71.
Poulsen MH, Rasmussen J, Edenbrandt L, et al. Bone scan index predicts outcome in patients with metastatic hormone-sensitive prostate cancer. BJU Int 2016;117:748–53.
Kaboteh R, Gjertsson P, Leek H, et al. Progression of bone metastases in patients with prostate cancer – automated detection of new lesions and calculation of bone scan index. EJNMMI Res 2013;3:64–9.
Ulmert D, Kaboteh R, Fox JJ, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol 2012;62:78–84.
Armstrong AJ, Kaboteh R, Carducci MA, et al. Assessment of the bone scan index in a randomised placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol 2014;32:1308–16.
Lin Y, Mao Q, Chen B, et al. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? A retrospective study. BMC Urol 2017;17:41.
Sathekge M, Lengana T, Maes A, et al. Ga-68 PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans. Eur J Nucl Med Mol Imaging 2018;45:226–34.
Omar F, El-Koha O, Sibanda W. Correlation between prostate-specific antigen and bone scan findings in patients with prostate cancer at Grey's Hospital, KwaZulu-Natal: a retrospective chart review. S Afr J Oncol 2020;04.
Manohar PR, Rather TA, Khan SH. Determination of the optimal cut-off value of serum prostate-specific antigen in the prediction of skeletal metastases on technetium-99m whole-body bone scan by receiver operating characteristic curve analysis. World J Nucl Med 2020;19:255–9.